Our Mission
To use Susavion’s patented MultiValent Peptide Mimetic (MVPM) Technology platform to harness the innate power of the immune system to combat diseases with non-toxic, safe and effective treatments.
At Susavion, we pride ourselves on doing things differently. We’re at the forefront of scientific innovation, leading the charge in the effort to solve some of healthcare’s most intractable problems. Our revolutionary therapy is safe and nontoxic, and we care about the people our research will benefit—always balancing our cutting-edge technology with our humanity.
Company Overview
-
Privately owned
-
Incorporated in 2006
-
15 issued patents, 3 pending
-
12 publications in peer-reviewed journals
